<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305682</url>
  </required_header>
  <id_info>
    <org_study_id>2005LS036</org_study_id>
    <secondary_id>UMN-MT-2005-02</secondary_id>
    <secondary_id>UMN-0507M70121</secondary_id>
    <nct_id>NCT00305682</nct_id>
  </id_info>
  <brief_title>Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant</brief_title>
  <official_title>Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping&#xD;
      them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. An&#xD;
      umbilical cord blood transplant may be able to replace blood-forming cells that were&#xD;
      destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells from a&#xD;
      donor can make an immune response against the body's normal cells. Giving sirolimus and&#xD;
      mycophenolate mofetil after the transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide&#xD;
      together with total-body irradiation followed by an umbilical cord blood transplant,&#xD;
      sirolimus, and mycophenolate mofetil works in treating patients with hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the one- and two-year survival of patients with hematologic malignancies&#xD;
           treated with a nonmyeloablative conditioning regimen comprising fludarabine,&#xD;
           cyclophosphamide, and total-body irradiation followed by umbilical cord blood&#xD;
           transplantation and post-transplant immunosuppression comprising sirolimus and&#xD;
           mycophenolate mofetil.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the six-month nonrelapse mortality of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the presence of chimerism in patients treated with this regimen at days 21,&#xD;
           60, 100, 180, and 365.&#xD;
&#xD;
        -  Determine the incidence of neutrophil engraftment by day 42 in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the incidence of platelet engraftment by six months in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the incidence of grade II-IV and grade III-IV acute graft-versus-host disease&#xD;
           (GVHD) at day 100 in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of chronic GVHD at one year in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the probability of overall survival within one or two years in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the probability of progression-free survival within one or two years in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of relapse or disease progression within one or two years in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized study. Patients are stratified into five disease groups: 1.&#xD;
      acute myeloid leukemia, myelodysplastic syndromes, chronic myelogenous leukemia [CML] in&#xD;
      first chronic phase and second chronic phase [CP2] after myeloid blast crisis; 2. acute&#xD;
      lymphoblastic leukemia, Burkitt's lymphoma, CML CP2 post lymphoid blast crisis, 3. large-cell&#xD;
      B and T-cell lymphoma, mantle cell lymphoma; 4. chronic lymphocytic leukemia/small&#xD;
      lymphocytic lymphoma, prolymphocytic leukemia, marginal zone B-cell lymphoma, follicular&#xD;
      lymphoma; 5. Hodgkin's lymphoma and multiple myeloma.&#xD;
&#xD;
        -  Nonmyeloablative conditioning: Patients receive fludarabine intravenously on days -6 to&#xD;
           -2 and cyclophosphamide IV on day -6. Patients who did not undergo prior autologous&#xD;
           transplant or who received â‰¤ 1 course of prior multiagent chemotherapy or no severely&#xD;
           immunosuppressive therapy in the past 3 months also receive anti-thymocyte globulin IV&#xD;
           on days -6 to -4. All patients also undergo total-body irradiation on day -1.&#xD;
&#xD;
        -  Umbilical cord blood transplant: Patients undergo umbilical cord blood transplantation&#xD;
           on day 0.&#xD;
&#xD;
        -  Post-transplant immunosuppression: Sirolimus will be administered starting at day -3&#xD;
           with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum&#xD;
           concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2&#xD;
           weeks, weekly until day +60, and as clinically indicated until day +100&#xD;
           post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at&#xD;
           day +100 and eliminated by day +180 post-transplantation. Patients also receive&#xD;
           mycophenolate mofetil IV on days -3 to 5 and then orally on days 6-30.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 320 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2005</start_date>
  <completion_date type="Actual">December 12, 2019</completion_date>
  <primary_completion_date type="Actual">December 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Were Alive at 1 Year Post Transplant</measure>
    <time_frame>1 Year</time_frame>
    <description>Overall Survival - Number of patients alive at 1 year post transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Were Alive at 2 Years Post Transplant</measure>
    <time_frame>2 Years</time_frame>
    <description>Overall Survival - Number of patients alive at 2 years post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were Dead at 6 Months After Study Completion</measure>
    <time_frame>Month 6</time_frame>
    <description>Incidence of Non-relapse mortality - Number of Patients Dead at 6 Months after study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Donor Chimerism at 21 Days</measure>
    <time_frame>21 days</time_frame>
    <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Donor Chimerism at 100 Days</measure>
    <time_frame>100 days</time_frame>
    <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Donor Chimerism at 180 Days</measure>
    <time_frame>180 Days</time_frame>
    <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Donor Chimerism at 365 Days</measure>
    <time_frame>365 days</time_frame>
    <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neutrophil Engraftment</measure>
    <time_frame>Day 42</time_frame>
    <description>Time to 1st 3 consecutive days with absolute neutrophil count (ANC) &gt; 5 x 10^8/L and percentage of patients with neutrophil recovery by day 42 (Cumulative incidence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Platelet Engraftment</measure>
    <time_frame>Day 180</time_frame>
    <description>Time to platelets &gt; 20,000 (first of 3 consecutive days) with no platelet transfusions for seven days and percentage of patients with platelet engraftment &gt;50,000 by day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Graft-versus-host Disease (GVHD)</measure>
    <time_frame>Day 100</time_frame>
    <description>Determine the incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) at day 100 post transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria used for staging.&#xD;
Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chronic Graft-Versus-Host Disease</measure>
    <time_frame>1 Year</time_frame>
    <description>Determine the incidence of chronic GVHD at 1 year after transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria. Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Progression-free Survival</measure>
    <time_frame>1 Year</time_frame>
    <description>Incidence of Progression-free survival - Number of patients who were alive and did not have disease progression. Patients with leukemia and lymphoma involving the bone marrow (BM) and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Progression-free Survival at 2 Years</measure>
    <time_frame>2 Years</time_frame>
    <description>Incidence of Progression-free survival - Number of patients who were alive and did not have disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Relapse (Incidence of Relapse)</measure>
    <time_frame>Year 1</time_frame>
    <description>Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Relapse (Incidence of Relapse) at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">295</enrollment>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm 1-Previous Autologous Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - No Prior Autologous Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - Refractory Leukemia/Lymphoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: MT2006-01 coenrolling patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 - Previous Autologous Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6 - No prior autologous transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.</description>
    <arm_group_label>Arm 2 - No Prior Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 3 - Refractory Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>Arm 6 - No prior autologous transplant</arm_group_label>
    <other_name>ATGAM</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.</description>
    <arm_group_label>Arm 1-Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 2 - No Prior Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 3 - Refractory Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>Arm 4: MT2006-01 coenrolling patients</arm_group_label>
    <arm_group_label>Arm 5 - Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 6 - No prior autologous transplant</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.</description>
    <arm_group_label>Arm 1-Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 2 - No Prior Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 3 - Refractory Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>Arm 4: MT2006-01 coenrolling patients</arm_group_label>
    <arm_group_label>Arm 5 - Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 6 - No prior autologous transplant</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil (MMF) 3 gram/day for patients who are â‰¥ 40 kg divided in 2 or 3 doses. Pediatric patient (&lt;40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.</description>
    <arm_group_label>Arm 1-Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 2 - No Prior Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 3 - Refractory Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>Arm 4: MT2006-01 coenrolling patients</arm_group_label>
    <arm_group_label>Arm 5 - Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 6 - No prior autologous transplant</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>One or 2 UCB units may be infused to achieve the required cell dose.</description>
    <arm_group_label>Arm 1-Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 2 - No Prior Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 3 - Refractory Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>Arm 4: MT2006-01 coenrolling patients</arm_group_label>
    <arm_group_label>Arm 5 - Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 6 - No prior autologous transplant</arm_group_label>
    <other_name>UCBT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total body irradiation</intervention_name>
    <description>Administered Day -1, 200 cGy</description>
    <arm_group_label>Arm 1-Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 2 - No Prior Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 3 - Refractory Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>Arm 4: MT2006-01 coenrolling patients</arm_group_label>
    <arm_group_label>Arm 5 - Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 6 - No prior autologous transplant</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.</description>
    <arm_group_label>Arm 1-Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 2 - No Prior Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 3 - Refractory Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>Arm 4: MT2006-01 coenrolling patients</arm_group_label>
    <arm_group_label>Arm 5 - Previous Autologous Transplant</arm_group_label>
    <arm_group_label>Arm 6 - No prior autologous transplant</arm_group_label>
    <other_name>rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age, Graft Cell Dose and Graft HLA Criteria&#xD;
&#xD;
          -  Subjects must be &lt;70 years old. Subjects ages â‰¥ 70 and â‰¤ 75 may be eligible if they&#xD;
             have a Co-Morbidity Scoring (HCT-CI) score â‰¤ 2.&#xD;
&#xD;
          -  The UCB graft is matched at 4-6 HLA-A, B, DRB1 antigens with the recipient.&#xD;
&#xD;
          -  Patients co-enrolled in MT-2006-01 Phase I Study of Infusion of Umbilical Cord Blood&#xD;
             Derived CD25+CD4+ T-Regulatory (Treg) Cells after Non-Myeloablative Cord\Blood&#xD;
             Transplantation will receive grafts composed of 2 UCB units.&#xD;
&#xD;
        Disease Criteria:&#xD;
&#xD;
          -  Acute Leukemias:&#xD;
&#xD;
               -  Acute myeloid leukemia: high risk complete remission 1 (CR1) (as evidenced by&#xD;
                  preceding myelodysplastic syndrome (MDS), high risk cytogenetics such as those&#xD;
                  associated with MDS or complex karyotype, &gt; 2 cycles to obtain CR or&#xD;
                  erythroblastic and megakaryocytic); second or greater CR.&#xD;
&#xD;
               -  Acute lymphoblastic leukemia/lymphoma: high risk CR1 as evidenced by high risk&#xD;
                  cytogenetics (e.g. t(9;22), t(1;19),t(4;11), other myeloid/lymphoid or mixed&#xD;
                  lineage leukemia [MLL] rearrangements, hypodiploidy or Ikaros family zinc finger&#xD;
                  1 [IKZF1]), &gt; 1 cycle to obtain CR or evidence of minimal residual disease (MRD).&#xD;
                  Patients in second or greater CR are also eligible.&#xD;
&#xD;
          -  Burkitt's lymphoma in CR2 or subsequent CR&#xD;
&#xD;
          -  Natural Killer cell malignancies&#xD;
&#xD;
          -  Chronic myelogenous leukemia: all types except refractory blast crisis. Chronic phase&#xD;
             patients must have failed or been intolerant to Gleevec&#xD;
&#xD;
          -  Myelodysplastic syndrome:&#xD;
&#xD;
          -  Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy sensitive&#xD;
             disease that has failed or patients who are ineligible for an autologous transplant.&#xD;
&#xD;
          -  Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone&#xD;
             B-cell lymphoma, follicular lymphoma, which have progressed within 12 months of&#xD;
             achieving a partial or complete remission. Patients who had remissions lasting &gt; 12&#xD;
             months, are eligible after at least two prior therapies. Patients with bulky disease&#xD;
             should be considered for debulking chemotherapy before transplant. Patients with&#xD;
             refractory disease are eligible, unless has bulky disease and an estimated tumor&#xD;
             doubling time of less than one month.&#xD;
&#xD;
          -  Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible&#xD;
             after initial therapy if chemotherapy sensitive.&#xD;
&#xD;
          -  Refractory leukemia or MDS.&#xD;
&#xD;
          -  Bone marrow failure syndromes, except for Fanconi Anemia&#xD;
&#xD;
          -  Myeloproliferative syndromes Patients who have undergone an autologous transplant &gt;12&#xD;
             months prior to allogeneic transplantation&#xD;
&#xD;
        Adequate Organ Function and Performance Status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 70 years with an available 5-6/6 HLA-A, B, DRB1 matched sibling donor&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Evidence of human immunodeficiency virus (HIV) infection or known HIV positive&#xD;
             serology&#xD;
&#xD;
          -  Current active serious infection&#xD;
&#xD;
          -  Unless in post-chemotherapy and radioimmunoconjugated antibody induced aplasia, when&#xD;
             he/she would be eligible for Arm 3, patients with acute leukemia in morphologic&#xD;
             relapse/ persistent disease defined as &gt; 5% blasts in normocellular bone marrow OR any&#xD;
             % blasts if blasts have unique morphologic markers (e.g. Auer rods) or associated&#xD;
             cytogenetic markers that allows morphologic relapse to be distinguished are not&#xD;
             eligible.&#xD;
&#xD;
          -  Chronic myelogenous leukemia (CML) in refractory blast crisis&#xD;
&#xD;
          -  Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressive on&#xD;
             salvage therapy. Stable disease is acceptable to move forward provided it is&#xD;
             non-bulky.&#xD;
&#xD;
          -  Active central nervous system malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio G. Brunstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582655/</url>
    <description>https://pubmed.ncbi.nlm.nih.gov/19179301/</description>
  </link>
  <reference>
    <citation>Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009 Mar 26;113(13):2902-5. doi: 10.1182/blood-2008-10-184093. Epub 2009 Jan 28.</citation>
    <PMID>19179301</PMID>
  </reference>
  <results_reference>
    <citation>Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009 Feb;15(2):214-22. doi: 10.1016/j.bbmt.2008.11.013.</citation>
    <PMID>19167681</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <results_first_submitted>October 8, 2020</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 8, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT00305682/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>7 patients were excluded from receiving the treatment as they were not eligible. 4 patients were removed from the study because the participating site withdrew the participation from the study</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1-Previous Autologous Transplant</title>
          <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 - No Prior Autologous Transplant</title>
          <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="P3">
          <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
          <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="P4">
          <title>Arm 4: MT2006-01 Coenrolling Patients</title>
          <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="P5">
          <title>Arm 5 - Previous Autologous Transplant</title>
          <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="P6">
          <title>Arm 6 - No Prior Autologous Transplant</title>
          <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="39"/>
                <participants group_id="P6" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="39"/>
                <participants group_id="P6" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1-Previous Autologous Transplant</title>
          <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2 - No Prior Autologous Transplant</title>
          <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="B3">
          <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
          <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="B4">
          <title>Arm 4: MT2006-01 Coenrolling Patients</title>
          <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="B5">
          <title>Arm 5 - Previous Autologous Transplant</title>
          <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="B6">
          <title>Arm 6 - No Prior Autologous Transplant</title>
          <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="34"/>
            <count group_id="B5" value="39"/>
            <count group_id="B6" value="35"/>
            <count group_id="B7" value="284"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="248"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Alive at 1 Year Post Transplant</title>
        <description>Overall Survival - Number of patients alive at 1 year post transplant</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Alive at 1 Year Post Transplant</title>
          <description>Overall Survival - Number of patients alive at 1 year post transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Alive at 2 Years Post Transplant</title>
        <description>Overall Survival - Number of patients alive at 2 years post transplant</description>
        <time_frame>2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Alive at 2 Years Post Transplant</title>
          <description>Overall Survival - Number of patients alive at 2 years post transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were Dead at 6 Months After Study Completion</title>
        <description>Incidence of Non-relapse mortality - Number of Patients Dead at 6 Months after study completion</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Dead at 6 Months After Study Completion</title>
          <description>Incidence of Non-relapse mortality - Number of Patients Dead at 6 Months after study completion</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Donor Chimerism at 21 Days</title>
        <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
        <time_frame>21 days</time_frame>
        <population>A total of 43 participants were not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Donor Chimerism at 21 Days</title>
          <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
          <population>A total of 43 participants were not evaluable</population>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" spread="25"/>
                    <measurement group_id="O2" value="73" spread="32"/>
                    <measurement group_id="O3" value="57" spread="29"/>
                    <measurement group_id="O4" value="77" spread="21"/>
                    <measurement group_id="O5" value="69" spread="32"/>
                    <measurement group_id="O6" value="68" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Donor Chimerism at 100 Days</title>
        <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
        <time_frame>100 days</time_frame>
        <population>A total of 85 participants were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Donor Chimerism at 100 Days</title>
          <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
          <population>A total of 85 participants were not evaluable.</population>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" spread="18"/>
                    <measurement group_id="O2" value="94" spread="21"/>
                    <measurement group_id="O3" value="100" spread="0"/>
                    <measurement group_id="O4" value="93" spread="23"/>
                    <measurement group_id="O5" value="85" spread="31"/>
                    <measurement group_id="O6" value="86" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Donor Chimerism at 180 Days</title>
        <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
        <time_frame>180 Days</time_frame>
        <population>A total of 134 participants were not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Donor Chimerism at 180 Days</title>
          <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
          <population>A total of 134 participants were not evaluable</population>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" spread="18"/>
                    <measurement group_id="O2" value="98" spread="6"/>
                    <measurement group_id="O3" value="88" spread="17"/>
                    <measurement group_id="O4" value="94" spread="16"/>
                    <measurement group_id="O5" value="91" spread="26"/>
                    <measurement group_id="O6" value="98" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Donor Chimerism at 365 Days</title>
        <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
        <time_frame>365 days</time_frame>
        <population>A total of 160 participants were not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Donor Chimerism at 365 Days</title>
          <description>Chimerism studies will be performed on the blood and bone marrow (BM). BM chimerism days 21 and 100, at 6 months and 1 year to determine the relative contribution of donor and recipient hematopoiesis.</description>
          <population>A total of 160 participants were not evaluable</population>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" spread="2"/>
                    <measurement group_id="O2" value="98" spread="12"/>
                    <measurement group_id="O4" value="99" spread="6"/>
                    <measurement group_id="O5" value="87" spread="34"/>
                    <measurement group_id="O6" value="100" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neutrophil Engraftment</title>
        <description>Time to 1st 3 consecutive days with absolute neutrophil count (ANC) &gt; 5 x 10^8/L and percentage of patients with neutrophil recovery by day 42 (Cumulative incidence).</description>
        <time_frame>Day 42</time_frame>
        <population>7 participants were not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutrophil Engraftment</title>
          <description>Time to 1st 3 consecutive days with absolute neutrophil count (ANC) &gt; 5 x 10^8/L and percentage of patients with neutrophil recovery by day 42 (Cumulative incidence).</description>
          <population>7 participants were not evaluable</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Platelet Engraftment</title>
        <description>Time to platelets &gt; 20,000 (first of 3 consecutive days) with no platelet transfusions for seven days and percentage of patients with platelet engraftment &gt;50,000 by day 100.</description>
        <time_frame>Day 180</time_frame>
        <population>13 participants were not evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Platelet Engraftment</title>
          <description>Time to platelets &gt; 20,000 (first of 3 consecutive days) with no platelet transfusions for seven days and percentage of patients with platelet engraftment &gt;50,000 by day 100.</description>
          <population>13 participants were not evaluable</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Graft-versus-host Disease (GVHD)</title>
        <description>Determine the incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) at day 100 post transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria used for staging.&#xD;
Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Graft-versus-host Disease (GVHD)</title>
          <description>Determine the incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) at day 100 post transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria used for staging.&#xD;
Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chronic Graft-Versus-Host Disease</title>
        <description>Determine the incidence of chronic GVHD at 1 year after transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria. Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic Graft-Versus-Host Disease</title>
          <description>Determine the incidence of chronic GVHD at 1 year after transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria. Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Progression-free Survival</title>
        <description>Incidence of Progression-free survival - Number of patients who were alive and did not have disease progression. Patients with leukemia and lymphoma involving the bone marrow (BM) and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Progression-free Survival</title>
          <description>Incidence of Progression-free survival - Number of patients who were alive and did not have disease progression. Patients with leukemia and lymphoma involving the bone marrow (BM) and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Progression-free Survival at 2 Years</title>
        <description>Incidence of Progression-free survival - Number of patients who were alive and did not have disease progression</description>
        <time_frame>2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Progression-free Survival at 2 Years</title>
          <description>Incidence of Progression-free survival - Number of patients who were alive and did not have disease progression</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Relapse (Incidence of Relapse)</title>
        <description>Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.</description>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Relapse (Incidence of Relapse)</title>
          <description>Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Relapse (Incidence of Relapse) at 2 Years</title>
        <description>Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Previous Autologous Transplant</title>
            <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - No Prior Autologous Transplant</title>
            <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
            <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: MT2006-01 Coenrolling Patients</title>
            <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - Previous Autologous Transplant</title>
            <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - No Prior Autologous Transplant</title>
            <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Relapse (Incidence of Relapse) at 2 Years</title>
          <description>Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1-Previous Autologous Transplant</title>
          <description>hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 - No Prior Autologous Transplant</title>
          <description>Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="E3">
          <title>Arm 3 - Refractory Leukemia/Lymphoma</title>
          <description>Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="E4">
          <title>Arm 4: MT2006-01 Coenrolling Patients</title>
          <description>Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="E5">
          <title>Arm 5 - Previous Autologous Transplant</title>
          <description>Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or â‰¥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
        <group group_id="E6">
          <title>Arm 6 - No Prior Autologous Transplant</title>
          <description>Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or â‰¤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow,other - relapse disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bone marrow cellularity - aplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>CNS hemorrhage/bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular, other disorder - substernal chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Primary Graft Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="71"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Progressive Disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Relapse</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukoencephalopathy associated with radiological findings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Guillamme Barre syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Idiopathic pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" events="10" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>pericardial effusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia (SVT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Engraftment syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegaloviral infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="98"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="114" subjects_affected="32" subjects_at_risk="98"/>
                <counts group_id="E2" events="51" subjects_affected="18" subjects_at_risk="71"/>
                <counts group_id="E3" events="23" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E4" events="27" subjects_affected="11" subjects_at_risk="34"/>
                <counts group_id="E5" events="101" subjects_affected="33" subjects_at_risk="39"/>
                <counts group_id="E6" events="122" subjects_affected="33" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>mastoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>neurotoxicity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dialysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Intubation</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="98"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="71"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="10" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="86" subjects_affected="39" subjects_at_risk="98"/>
                <counts group_id="E2" events="81" subjects_affected="37" subjects_at_risk="71"/>
                <counts group_id="E3" events="15" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E4" events="28" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E5" events="37" subjects_affected="18" subjects_at_risk="39"/>
                <counts group_id="E6" events="60" subjects_affected="20" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>pulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rashes due to drug toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Claudio G. Brunstein MD, PhD</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-3918</phone>
      <email>bruns072@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

